New drug combo tested to shrink tumors before kidney cancer surgery
NCT ID NCT05733715
Summary
This study is testing whether giving cancer drugs before surgery can help the immune system fight kidney cancer. About 30 patients with high-risk kidney cancer will receive either pembrolizumab alone or pembrolizumab combined with lenvatinib before their tumor is removed. The main goal is to see how these treatments affect immune cells in the blood and tumor, not to cure the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center at University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.